{"protocolSection": {"identificationModule": {"nctId": "NCT01107743", "orgStudyIdInfo": {"id": "A3841063"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "Amlodipine/Atorvastatin (Caduet\u00ae) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)", "officialTitle": "Caduet\u00ae Drug Use Investigation (Regulatory Post Marketing Commitment Plan)"}, "statusModule": {"statusVerifiedDate": "2021-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-06"}, "primaryCompletionDateStruct": {"date": "2012-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-04-20", "studyFirstSubmitQcDate": "2010-04-20", "studyFirstPostDateStruct": {"date": "2010-04-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-04-09", "resultsFirstSubmitQcDate": "2013-04-09", "resultsFirstPostDateStruct": {"date": "2013-05-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-01-26", "lastUpdatePostDateStruct": {"date": "2021-01-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin (Caduet\u00ae Combination Tablets) in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.", "detailedDescription": "All the subjects whom an investigator prescribes the first Amlodipine /Atorvastatin (Caduet\u00ae) Combination Tablets should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random."}, "conditionsModule": {"conditions": ["Hypertension", "Angina Pectoris", "Hypercholesterolemia", "Familial Hypercholesterolemia"], "keywords": ["Hypertension", "Angina pectoris", "Hypercholesterolemia", "Familial hypercholesterolemia", "Japanese", "caduet", "Regulatory Post Marketing Commitment Plan"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "CASE_ONLY", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1291, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Amlodipine and Atorvastatin Combination Tablet", "description": "Subjects taking Amlodipine and Atorvastatin Combination Tablets", "interventionNames": ["Drug: Amlodipine/Atorvastatin"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine/Atorvastatin", "description": "Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.\n\nSubjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.\n\nFor oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.\n\nAmlodipine\n\n* Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.\n* Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin\n* Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.\n* Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily.", "armGroupLabels": ["Amlodipine and Atorvastatin Combination Tablet"], "otherNames": ["Caduet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Treatment Related Adverse Events.", "description": "Adverse events mean all unfavorable events that occur in patients after administration of Caduet, irrespective of causal relationship to Caduet (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Caduet.", "timeFrame": "8 weeks"}, {"measure": "Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypertension.", "description": "The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results for Hypertension.", "timeFrame": "8 weeks"}, {"measure": "Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Angina Pectoris.", "description": "The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and enteterd the results for Angina Pectoris.", "timeFrame": "8 weeks"}, {"measure": "Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypercholesterolemia or Familial Hypercholesterolemia.", "description": "The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results for Hypercholesterolemia or Familial Hypercholesterolemia.", "timeFrame": "8 weeks"}], "secondaryOutcomes": [{"measure": "Number of Treatment Related Unlisted Adverse Events in Japanese Package Insert.", "description": "Adverse events mean all unfavorable events that occur in patients after administration of Caduet, irrespective of causal relationship to Caduet (including clinically problematic abnormal changes in laboratory test values). Number of Treatment Related Adverse Events were evaluated in company with the causal relationship to Caduet. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age.", "description": "Number of participants with Treatment Related Adverse Events (TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether \\<65 years or \\>=65 years is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hypertension is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension Severity.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypertension severity, \"Class\u2160, Class\u2161, or Class\u2162\" is significant risk factor. Hypertension severity is defined by Guideline for the Management of hypertension (The Japan Society of Hypertension).", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Angina pectoris is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hypercholesterolemia is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia Expression Type.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypercholesterolemia expression type, \"\u2160, \u2161a, \u2161b, \u2162, \u2163, or \u2164\" is significant risk factor. Hypercholesterolemia expression types are defined by Japan Atherosclerosis Society Guideline for Prevention of Atherosclerosis Cardiovascular Diseases.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Familial Hypercholesterolemia is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hepatic Dysfunction.", "description": "Number of participants with Treatment Related Adverse Events (TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Renal Dysfunction.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Concomitant Drugs is significant risk factor.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypertension -Gender.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Hypertension.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypertension -Age.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether \\<65 years or \\>=65 is significant risk factor for Hypertension.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypertension -Hypertension Severity.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypertension severity, \"Class\u2160, Class\u2161, or Class\u2162\" is significant risk factor for Hypertension. Hypertension severity is defined by Guideline for the Management of hypertension (The Japan Society of Hypertension).", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypertension -Hepatic Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Hypertension.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Hypertension.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypertension -Complications.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor for Hypertension.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypertension -Concomitant Drugs.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Hypertension.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Angina Pectoris -Gender.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Angina Pectoris.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Angina Pectoris -Age.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether \\<65 years or \\>=65 is significant risk factor for Angina Pectoris.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Angina Pectoris -Angina Pectoris Severity.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Angina Pectoris functional classification Severity, \"Class1, Class2, Class3, or Class4\" is significant risk factor for Angina Pectoris. Angina Pectoris functional classification Severity is defined by Canadian Cardiovascular Society functional Classification of Angina.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Angina Pectoris -Hepatic Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Angina Pectoris.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Angina Pectoris -Renal Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Angina Pectoris.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Angina Pectoris -Complications.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Angina Pectoris is significant risk factor for Angina Pectoris.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Angina Pectoris -Concomitant Drugs.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Angina Pectoris.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Gender.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Age.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether \\<65 years or \\>=65 is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "timeFrame": "8 weeks"}, {"measure": "Risk Factor for the Proportion of Responders of Amlodipine/Atorvastatin Combination Tablets for Hypercholesterolemia or Familial Hypercholesterolemia - Hypercholesterolemia Expression Type.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypercholesterolemia expression type, \"\u2160, \u2161a, \u2161b, \u2162, \u2163, or \u2164\" is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. Hypercholesterolemia expression types are defined by Japan Atherosclerosis Society Guideline for Prevention of Atherosclerosis Cardiovascular Diseases.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Hepatic Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Renal Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Complications.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "timeFrame": "8 weeks"}, {"measure": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Concomitant Drugs.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or Female subjects intend to treat their cardiovascular disease who are prescribed Amlodipine /Atorvastatin (Caduet\u00ae) Combination Tablets by their Physicians\n\nExclusion Criteria:\n\nSubjects who have been prescribed Amlodipine /Atorvastatin (Caduet\u00ae) Combination Tablets before.", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "The subjects whom an investigator involving A3841063 prescribes the Amlodipine /Atorvastatin (Caduet\u00ae) Combination Tablets.", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3841063&StudyName=Amlodipine/Atorvastatin%20%28Caduet%AE%29%20Drug%20Use%20Investigation%20%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29%20"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "This was a phase 4, observational, open-label study conducted in Participants who were prescribed Amlodipine /Atorvastatin (Caduet\u00ae) Combination Tablets by their treating physician per usual clinical practice. Study drug was not provided by the Sponsor.", "groups": [{"id": "FG000", "title": "Amlodipine and Atorvastatin Combination Tablet", "description": "Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1291"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1245"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "46"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "46"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Amlodipine and Atorvastatin Combination Tablet", "description": "Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1245"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "377"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "868"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "787"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "458"}]}]}]}, {"title": "Type of Disease", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hypertension", "categories": [{"measurements": [{"groupId": "BG000", "value": "1237"}]}]}, {"title": "Angina pectoris", "categories": [{"measurements": [{"groupId": "BG000", "value": "183"}]}]}, {"title": "Hypercholesterolemia", "categories": [{"measurements": [{"groupId": "BG000", "value": "1227"}]}]}, {"title": "Familial hypercholesterolemia", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Treatment Related Adverse Events.", "description": "Adverse events mean all unfavorable events that occur in patients after administration of Caduet, irrespective of causal relationship to Caduet (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Caduet.", "populationDescription": "The safety analysis population consist of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine and Atorvastatin Combination Tablet", "description": "Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1245"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypertension.", "description": "The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results for Hypertension.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine and Atorvastatin Combination Tablet", "description": "Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1202"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1151"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Angina Pectoris.", "description": "The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and enteterd the results for Angina Pectoris.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Angina Pectoris in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine and Atorvastatin Combination Tablet", "description": "Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "163"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypercholesterolemia or Familial Hypercholesterolemia.", "description": "The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results for Hypercholesterolemia or Familial Hypercholesterolemia.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypercholesterolemia or Familial Hypercholesterolemia in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine and Atorvastatin Combination Tablet", "description": "Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1057"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1034"}]}]}]}, {"type": "SECONDARY", "title": "Number of Treatment Related Unlisted Adverse Events in Japanese Package Insert.", "description": "Adverse events mean all unfavorable events that occur in patients after administration of Caduet, irrespective of causal relationship to Caduet (including clinically problematic abnormal changes in laboratory test values). Number of Treatment Related Adverse Events were evaluated in company with the causal relationship to Caduet. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.", "populationDescription": "The safety analysis population consists of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine and Atorvastatin Combination Tablet", "description": "Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1245"}]}], "classes": [{"title": "Anaemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Hypoproteinaemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Male", "description": "Male participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Female", "description": "Female participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "458"}, {"groupId": "OG001", "value": "787"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Gender\". The null hypothesis is there is no difference between \"male and female\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.812", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age.", "description": "Number of participants with Treatment Related Adverse Events (TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether \\<65 years or \\>=65 years is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "<65 Years", "description": "Participants with \\<65 years who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": ">=65 Years", "description": "Participants with \\>=65 years who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "377"}, {"groupId": "OG001", "value": "868"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Age\". The null hypothesis is there is no difference between \"\\<65 years and \\>=65 years\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=1.000", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hypertension is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Hypertension", "description": "Participants without Hypertension who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Hypertension", "description": "Participants with Hypertension who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "1237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Hypertension\". The null hypothesis is there is no difference between \"with Hypetension and without Hypertension\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=1.000", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension Severity.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypertension severity, \"Class\u2160, Class\u2161, or Class\u2162\" is significant risk factor. Hypertension severity is defined by Guideline for the Management of hypertension (The Japan Society of Hypertension).", "populationDescription": "The safety analysis population consists of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Class\u2160", "description": "Participants with Class\u2160 Hypertension who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Class\u2161", "description": "Participants with Class\u2161 Hypertension who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG002", "title": "Class\u2162", "description": "Participants with Class\u2162 Hypertension who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "656"}, {"groupId": "OG001", "value": "351"}, {"groupId": "OG002", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "The risk factor tested was \"Hypertension severity\". The null hypothesis is there is no difference among \"Class\u2160Hypertension, Class\u2161 Hypertension, and Class\u2162 Hypertension\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.112", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Angina pectoris is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Angina Pectoris", "description": "Participants without Angina Pectoris who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Angina Pectoris", "description": "Participants with Angina Pectoris who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1062"}, {"groupId": "OG001", "value": "183"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Angina Pectoris\". The null hypothesis is there is no difference between \"with Angina Pectoris and without Angina Pectoris\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.093", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hypercholesterolemia is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Hypercholesterolemia", "description": "Participants without Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Hypercholesterolemia", "description": "Participants with Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "1227"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Hypercholesterolemia\". The null hypothesis is there is no difference between \"with Hypercholesterolemia and without Hypercholesterolemia\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=1.000", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia Expression Type.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypercholesterolemia expression type, \"\u2160, \u2161a, \u2161b, \u2162, \u2163, or \u2164\" is significant risk factor. Hypercholesterolemia expression types are defined by Japan Atherosclerosis Society Guideline for Prevention of Atherosclerosis Cardiovascular Diseases.", "populationDescription": "The safety analysis population consists of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Type \u2160", "description": "Participants with expression type \u2160 Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Type \u2161a", "description": "Participants with expression type \u2161a Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG002", "title": "Type \u2161b", "description": "Participants with expression type \u2161b Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG003", "title": "Type \u2162", "description": "Participants with expression type \u2162 Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG004", "title": "Type \u2163", "description": "Participants with expression type \u2163 Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG005", "title": "Type \u2164", "description": "Participants with expression type \u2164 Hypercholesterolemia who took Amlodipine /Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "609"}, {"groupId": "OG002", "value": "207"}, {"groupId": "OG003", "value": "12"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003", "OG004", "OG005"], "groupDescription": "The risk factor tested was \"Hypercholesterolemia expression type\". The null hypothesis is there is no difference among \"expression type \u2160, expression type \u2161a, expression type \u2161b, expression type \u2162, expression type, expression type \u2163, and expression type \u2164\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.839", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Familial Hypercholesterolemia is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Familial Hypercholesterolemia", "description": "Participants without Familial Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Familial Hypercholesterolemia", "description": "Participants with Familial Hypercholesterolemia who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1231"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Familial Hypercholesterolemia\". The null hypothesis is there is no difference between \"with Familial Hypercholesterolemia and without Familial Hypercholesterolemia\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=1.000", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hepatic Dysfunction.", "description": "Number of participants with Treatment Related Adverse Events (TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Hepatic Dysfunction", "description": "Participants without Hepatic Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Hepatic Dysfunction", "description": "Participants with Hepatic Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1087"}, {"groupId": "OG001", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Hepatic Dysfunction\". The null hypothesis is there is no difference between \"with Hepatic Dysfunction and without Hepatic Dysfunction\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=1.000", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Renal Dysfunction.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Renal Dysfunction", "description": "Participants without Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Renal Dysfunction", "description": "Participants with Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1123"}, {"groupId": "OG001", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Renal Dysfunction\". The null hypothesis is there is no difference between \"with Renal Dysfunction and without Renal Dysfunction\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.644", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Complications", "description": "Participants without Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Complications", "description": "Participants with Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "568"}, {"groupId": "OG001", "value": "677"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Complications\". The null hypothesis is there is no difference between \"with Complications and without Complications\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.155", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs.", "description": "Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Concomitant Drugs is significant risk factor.", "populationDescription": "The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Concomitant Drugs", "description": "Participants without Concomitant Drugs who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Concomitant Drugs", "description": "Participants with Concomitant Drugs who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "360"}, {"groupId": "OG001", "value": "885"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Concomitant Drugs\". The null hypothesis is there is no difference between \"with Concomitant Drugs and without Concomitant Drugs\" in the Incidence Rate of Treatment Related Adverse Events(TRAEs).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.305", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypertension -Gender.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Hypertension.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Male", "description": "Male Participants who took Amlodipine /Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Female", "description": "Female Participants who took Amlodipine /Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "438"}, {"groupId": "OG001", "value": "764"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "415"}, {"groupId": "OG001", "value": "736"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Gender\". The null hypothesis is there is no difference between \"males and females\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.234", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypertension -Age.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether \\<65 years or \\>=65 is significant risk factor for Hypertension.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "<65 Years", "description": "Participants with \\<65 years who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": ">=65 Years", "description": "Participants with \\>=65 years who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "365"}, {"groupId": "OG001", "value": "837"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "347"}, {"groupId": "OG001", "value": "804"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Age\". The null hypothesis is there is no difference between \"\\<65 years and \\>=65 years\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.439", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypertension -Hypertension Severity.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypertension severity, \"Class\u2160, Class\u2161, or Class\u2162\" is significant risk factor for Hypertension. Hypertension severity is defined by Guideline for the Management of hypertension (The Japan Society of Hypertension).", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Class\u2160", "description": "Participants with Class\u2160 Hypertension who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Class\u2161", "description": "Participants with Class\u2161 Hypertension who took Amlodipine /Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG002", "title": "Class\u2162", "description": "Participants with Class \u2162 Hypertension who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "644"}, {"groupId": "OG001", "value": "339"}, {"groupId": "OG002", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "325"}, {"groupId": "OG002", "value": "85"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "The risk factor tested was \"Hypertension severity\". The null hypothesis is there is no difference among \"Class\u2160Hypertension, Class\u2161 Hypertension, and Class\u2162 Hypertension\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.761", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypertension -Hepatic Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Hypertension.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Hepatic Dysfunction", "description": "Participants without Hepatic Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Hepatic Dysfunction", "description": "Participants with Hepatic Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1053"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1008"}, {"groupId": "OG001", "value": "131"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Hepatic Dysfunction\". The null hypothesis is there is no difference between \"with and without Hepatic Dysfunction\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=1.000", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Hypertension.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Renal Dysfunction", "description": "Participants without Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Renal Dysfunction", "description": "Participants with Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1085"}, {"groupId": "OG001", "value": "104"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1036"}, {"groupId": "OG001", "value": "102"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Renal Dysfunction\". The null hypothesis is there is no difference between \"with and without Renal Dysfunction\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.310", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypertension -Complications.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor for Hypertension.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Complications", "description": "Participants without Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Complications", "description": "Participants with Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "555"}, {"groupId": "OG001", "value": "647"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "527"}, {"groupId": "OG001", "value": "624"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Complications\". The null hypothesis is there is no difference between \"with and without Complications\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.251", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypertension -Concomitant Drugs.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Hypertension.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Concomitant Drugs", "description": "Participants without Concomitant Drugs who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Concomitant Drugs", "description": "Participants with Concomitant Drugs who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "355"}, {"groupId": "OG001", "value": "847"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "339"}, {"groupId": "OG001", "value": "812"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Concomitant Drugs\". The null hypothesis is there is no difference between \"with and without Concomitant Drugs\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.756", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Angina Pectoris -Gender.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Angina Pectoris.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Angina Pectoris in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Male", "description": "Male Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Female", "description": "Female Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "88"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Gender\". The null hypothesis is there is no difference between \"males and females\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.706", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Angina Pectoris -Age.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether \\<65 years or \\>=65 is significant risk factor for Angina Pectoris.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Angina Pectoris in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "<65 Years", "description": "Participants with \\<65 years who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": ">=65 Years", "description": "Participants with \\>=65 years who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "118"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Age\". The null hypothesis is there is no difference between \"\\<65 years and \\>=65 years\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.192", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Angina Pectoris -Angina Pectoris Severity.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Angina Pectoris functional classification Severity, \"Class1, Class2, Class3, or Class4\" is significant risk factor for Angina Pectoris. Angina Pectoris functional classification Severity is defined by Canadian Cardiovascular Society functional Classification of Angina.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Angina Pectoris in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Class1", "description": "Participants with Class1 Angina Pectoris who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Class2", "description": "Participants with Class2 Angina Pectoris who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG002", "title": "Class3", "description": "Participants with Class3 Angina Pectoris who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG003", "title": "Class4", "description": "Participants with Class4 Angina Pectoris who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "groupDescription": "The risk factor tested was \"Angina Pectoris Severity\". The null hypothesis is there is no difference among \"Class1, Class2, Class3, and Class4\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.005", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Angina Pectoris -Hepatic Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Angina Pectoris.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Angina Pectoris in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Hepatic Dysfunction", "description": "Participants without Hepatic Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Hepatic Dysfunction", "description": "Participants with Hepatic Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Hepatic Dysfunction\". The null hypothesis is there is no difference between \"with and without Hepatic Dysfunction\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=1.000", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Angina Pectoris -Renal Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Angina Pectoris.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Angina Pectoris in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Renal Dysfunction", "description": "Participants without Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Renal Dysfunction", "description": "Participants with Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Renal Dysfunction\". The null hypothesis is there is no difference between \"with and without Renal Dysfunction\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.596", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Angina Pectoris -Complications.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Angina Pectoris is significant risk factor for Angina Pectoris.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Angina Pectoris in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Complications", "description": "Participants without Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Complications", "description": "Participants with Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "106"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Complications\". The null hypothesis is there is no difference between \"with and without Complications\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.252", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Angina Pectoris -Concomitant Drugs.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Angina Pectoris.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Angina Pectoris in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Concomitant Drugs", "description": "Participants without Concomitant Drugs who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Concomitant Drugs", "description": "Participants with Concomitant Drugs who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "147"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "141"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Concomitant Drugs\". The null hypothesis is there is no difference between \"with and without Concomitant Drugs\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=1.000", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Gender.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypercholesterolemia or Familial Hypercholesterolemia in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Male", "description": "Male Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Female", "description": "Female Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "390"}, {"groupId": "OG001", "value": "667"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "380"}, {"groupId": "OG001", "value": "654"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Gender\". The null hypothesis is there is no difference between \"males and females\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.518", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Age.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether \\<65 years or \\>=65 is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypercholesterolemia or Familial Hypercholesterolemia in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "<65 Years", "description": "Participants with \\<65 years who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": ">=65 Years", "description": "Participants with \\>=65 years who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "744"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "729"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Age\". The null hypothesis is there is no difference between \"\\<65 years and \\>=65 years\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.645", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factor for the Proportion of Responders of Amlodipine/Atorvastatin Combination Tablets for Hypercholesterolemia or Familial Hypercholesterolemia - Hypercholesterolemia Expression Type.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypercholesterolemia expression type, \"\u2160, \u2161a, \u2161b, \u2162, \u2163, or \u2164\" is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. Hypercholesterolemia expression types are defined by Japan Atherosclerosis Society Guideline for Prevention of Atherosclerosis Cardiovascular Diseases.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypercholesterolemia or Familial Hypercholesterolemia in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Type \u2160", "description": "Participants with expression type \u2160 who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "Type \u2161a", "description": "Participants with expression type \u2161a who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG002", "title": "Type \u2161b", "description": "Participants with expression type \u2161b who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG003", "title": "Type \u2162", "description": "Participants with expression type \u2162 who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG004", "title": "Type \u2163", "description": "Participants with expression type \u2163 who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG005", "title": "Type \u2164", "description": "Participants with expression type \u2164 who took Amlodipine /Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "541"}, {"groupId": "OG002", "value": "187"}, {"groupId": "OG003", "value": "11"}, {"groupId": "OG004", "value": "5"}, {"groupId": "OG005", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "533"}, {"groupId": "OG002", "value": "180"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003", "OG004", "OG005"], "groupDescription": "The risk factor tested was \"Hypercholesterolemia expression type\". The null hypothesis is there is no difference among \"expression type \u2160, expression type \u2161a, expression type \u2161b, expression type \u2162, expression type, expression type \u2163, and expression type \u2164\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.130", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Hepatic Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypercholesterolemia or Familial Hypercholesterolemia in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Hepatic Dysfunction", "description": "Participants without Hepatic Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Hepatic Dysfunction", "description": "Participants with Hepatic Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "922"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "904"}, {"groupId": "OG001", "value": "122"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Hepatic Dysfunction\". The null hypothesis is there is no difference between \"with and without Hepatic Dysfunction\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.185", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Renal Dysfunction.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypercholesterolemia or Familial Hypercholesterolemia in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Renal Dysfunction", "description": "Participants without Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Renal Dysfunction", "description": "Participants with Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "959"}, {"groupId": "OG001", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "937"}, {"groupId": "OG001", "value": "88"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Renal Dysfunction\". The null hypothesis is there is no difference between \"with and without Renal Dysfunction\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.714", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Complications.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypercholesterolemia or Familial Hypercholesterolemia in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Complications", "description": "Participants without Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Complications", "description": "Participants with Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "492"}, {"groupId": "OG001", "value": "565"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "482"}, {"groupId": "OG001", "value": "552"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Complications\". The null hypothesis is there is no difference between \"with and without Complications\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.835", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Concomitant Drugs.", "description": "Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia.", "populationDescription": "The efficacy analysis population basically consists of the evaluable cases with Hypercholesterolemia or Familial Hypercholesterolemia in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Without Concomitant Drugs", "description": "Participants without Concomitant Drugs who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}, {"id": "OG001", "title": "With Concomitant Drugs", "description": "Participants with Concomitant Drugs who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}, {"groupId": "OG001", "value": "747"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "306"}, {"groupId": "OG001", "value": "728"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The risk factor tested was \"Concomitant Drugs\". The null hypothesis is there is no difference between \"with and without Concomitant Drugs\" in the participants of responders.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "=0.252", "statisticalMethod": "Fisher Exact", "ciNumSides": "TWO_SIDED"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.", "eventGroups": [{"id": "EG000", "title": "Amlodipine and Atorvastatin Combination Tablet", "description": "Participants who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert.", "seriousNumAffected": 1, "seriousNumAtRisk": 1245, "otherNumAffected": 17, "otherNumAtRisk": 1245}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}], "otherEvents": [{"term": "Hypoproteinaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Eyelid oedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1245}]}, {"term": "Hypoaesthesia oral", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Gingival swelling", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Liver disorder", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Hyperbilirubinaemia", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1245}]}, {"term": "Periarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Musculoskeletal stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Feeling abnormal", "organSystem": "General disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 1245}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA-J 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1245}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000000787", "term": "Angina Pectoris"}, {"id": "D000006938", "term": "Hyperlipoproteinemia Type II"}, {"id": "D000006937", "term": "Hypercholesterolemia"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006949", "term": "Hyperlipidemias"}, {"id": "D000050171", "term": "Dyslipidemias"}, {"id": "D000052439", "term": "Lipid Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000008052", "term": "Lipid Metabolism, Inborn Errors"}, {"id": "D000008661", "term": "Metabolism, Inborn Errors"}, {"id": "D000030342", "term": "Genetic Diseases, Inborn"}, {"id": "D000006951", "term": "Hyperlipoproteinemias"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002637", "term": "Chest Pain"}, {"id": "D000010146", "term": "Pain"}, {"id": "D000009461", "term": "Neurologic Manifestations"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M9988", "name": "Hypercholesterolemia", "asFound": "Hypercholesterolemia", "relevance": "HIGH"}, {"id": "M4117", "name": "Angina Pectoris", "asFound": "Angina Pectoris", "relevance": "HIGH"}, {"id": "M10000", "name": "Hyperlipidemias", "relevance": "LOW"}, {"id": "M10002", "name": "Hyperlipoproteinemias", "relevance": "LOW"}, {"id": "M9989", "name": "Hyperlipoproteinemia Type II", "asFound": "Familial Hypercholesterolemia", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M26181", "name": "Dyslipidemias", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M27029", "name": "Lipid Metabolism Disorders", "relevance": "LOW"}, {"id": "M11641", "name": "Metabolism, Inborn Errors", "relevance": "LOW"}, {"id": "M11054", "name": "Lipid Metabolism, Inborn Errors", "relevance": "LOW"}, {"id": "M23686", "name": "Genetic Diseases, Inborn", "relevance": "LOW"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M6546", "name": "Coronary Artery Disease", "relevance": "LOW"}, {"id": "M19506", "name": "Myocardial Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M13066", "name": "Pain", "relevance": "LOW"}, {"id": "M5882", "name": "Chest Pain", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000487936", "term": "Amlodipine, atorvastatin drug combination"}, {"id": "D000069059", "term": "Atorvastatin"}], "ancestors": [{"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M351", "name": "Atorvastatin", "asFound": "General", "relevance": "HIGH"}, {"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M223699", "name": "Amlodipine, atorvastatin drug combination", "asFound": "Elafibranor", "relevance": "HIGH"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}